scholarly journals Summary of the first annual Genitourinary Medical Oncology Conference Renal Cell Carcinoma Forum

2012 ◽  
Vol 1 (2S) ◽  
Author(s):  
Lori A. Wood ◽  
Bernard Escudier ◽  
Neil Reaume
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Medical Oncology ◽  
Practical Experience ◽  
Sarcomatoid Renal Cell Carcinoma

The first annual Canadian Genitourinary Medical Oncology Conference washeld in June 2006 before the Canadian Urology Association Annual Meeting.This article summarizes 3 presentations that took place as part of the Renal CellCarcinoma Forum: “Treatment of Metastatic Renal Cell Carcinoma: 2006 andBeyond” was presented by Dr. Bernard Escudier; “Practical Experience withTargeted Therapy,” by Dr. Lori Wood; and “Sarcomatoid Renal Cell Carcinoma,”by Dr. Neil Reaume.

Medical Treatment of Metastatic Renal Cell Carcinoma

1980 ◽  
Vol 66 (2) ◽  
pp. 235-240 ◽  
Author(s):  
Umberto Tirelli ◽  
Sergio Frustaci ◽  
Enzo Galligioni ◽  
Andrea Veronesi ◽  
Mauro G. Trovò ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Medical Treatment ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Medical Oncology ◽  
Primary Treatment ◽  
Duration Of Response ◽  
Treatment Agent ◽  
Metastatic Rcc

Thirty five patients with metastatic RCC were observed over a 57 months period in our Division of Radiotherapy and Medical Oncology, and 30 are evaluable for this analysis. MPA was selected as primary treatment agent in 23 patients, VLB singly, in combination with MPA or in combination with CCNU was used in 1.4 and 2 patients. With MPA the TR rate was 3/23 (1 CR and 2 PR). Duration of response for the patient with CR was 6 months whereas for the patients with PR was 21 and 14 months respectively. 4 additional patients showed NC. With VLB-MPA the TR rate was 1/4 (1 PR). Duration of PR was 3 months. The median duration of survival for the 11 patients with CR, PR and NC was 14 months whereas for the 19 patients with NR was 7 months (p < 0.01). TES and TAM showed no or minimal activity as second treatment agents.

Combination of Gemcitabine and Doxorubicin in Rapidly Progressive Metastatic Renal Cell Carcinoma and/or Sarcomatoid Renal Cell Carcinoma

Oncology ◽  
2011 ◽  
Vol 80 (3-4) ◽  
pp. 214-218 ◽  
Author(s):  
G. Roubaud ◽  
M. Gross-Goupil ◽  
H. Wallerand ◽  
H. de Clermont ◽  
M.S. Dilhuydy ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Sarcomatoid Renal Cell Carcinoma

Outcome of Patients With Metastatic Sarcomatoid Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium

2015 ◽  
Vol 13 (2) ◽  
pp. e79-e85 ◽  
Author(s):  
Christos E. Kyriakopoulos ◽  
Namita Chittoria ◽  
Toni K. Choueiri ◽  
Nils Kroeger ◽  
Jae-Lyun Lee ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Sarcomatoid Renal Cell Carcinoma

CLOVIZ: Clinical outcomes visualization of IMDC criteria in metastatic renal cell carcinoma for patient-centered decision making.

2017 ◽  
Vol 35 (6_suppl) ◽  
pp. 527-527
Author(s):  
Anobel Y. Odisho ◽  
Sumanta K. Pal ◽  
Michael Shapiro ◽  
Ashley Dixon ◽  
Connor Wells ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Clinical Application ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Medical Oncology ◽  
Task Complexity ◽  
Interactive Visualization ◽  
Medical Oncologists ◽  
Clinical Scenarios

527 Background: The International Metastatic Renal Cell Carcinoma Database (IMDC) Criteria (Heng Criteria) is a validated risk prediction tool for patients with metastatic renal cell carcinoma (mRCC). It provides valuable prognostic data but clinical application can be challenging due to limited available tools. We created an interactive visualization to facilitate clinical application of IMDC Criteria. Methods: A multi-institutional cohort of 436 patients with mRCC was used to create an interactive visualization depicting IMDC Criteria at the patient level. Usability testing was performed with non-medical lay-users and medical oncology fellows. Subjects used the tool to calculate median survival times based on IMDC Criteria in six increasingly complex clinical scenarios. Confidence using the tool was surveyed and measured along a 5-point Likert scale. Results: The interactive visualization is available at http://faculty.washington.edu/odisho . 400 lay-users and 15 medical oncology fellows completed clinical scenarios and surveys. Overall, lay-users were able to obtain the exact correct answer in 48% of scenarios, compared to 60% of medical oncology fellows. The proportion of exact correct answers decreased with increasing task complexity, but the proportion of answers within 25% of the expected answer remained stable at 68-78% for lay-users and 73-93% for medical oncology fellows. When surveying usability, 65% of lay-users felt it was easy to use, compared to 80% of fellows, and 83%-87% felt it became intuitive with increasing use. Among lay-users, 69-77% were confident selecting lab values and drugs, compared to 87-93% of medical oncology fellows. 75% of lay-users felt it helped them better understand survival in mRCC. 68% of lay-users wanted to use a similar tool with their doctor, while 87% of medical oncologists wanted to use this with patients, and 93% wanted to incorporate it into their clinical practice in some way. Conclusions: A graphical method of interacting with a validated nomogram for mRCC outcomes provides real-time individual level data that can be used by untrained nonmedical users and medical oncologists, with potential for use in the clinic setting.

1103: Laparoscopic Salvage Nephrectomy after Targeted Neoadjuvant Therapy for Metastatic Renal Cell Carcinoma: Initial Results

2007 ◽  
Vol 177 (4S) ◽  
pp. 364-364 ◽  
Author(s):  
Surena F. Matin ◽  
Christopher G. Wood ◽  
Shi-Ming Tu ◽  
Nizar M. Tannir ◽  
Eric Jonasch
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Neoadjuvant Therapy ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Initial Results

637: Establishing a Porcine Model for the Accelerated Development of Cancer Vaccines for Patients with Metastatic Renal Cell Carcinoma

2005 ◽  
Vol 173 (4S) ◽  
pp. 173-174
Author(s):  
Quinton V. Cancel ◽  
Benjamin K. Yang ◽  
Zhen Su ◽  
Jens Dannull ◽  
Philipp Dahm ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Cancer Vaccines ◽  
Porcine Model

1716: Pharmaco-Angio-CT is Superior to 4 Phase Helical CT in the Detection of Recurrent Metastatic Renal Cell Carcinoma

2006 ◽  
Vol 175 (4S) ◽  
pp. 551-552
Author(s):  
Erich K. Lang ◽  
Richard J. Macchia ◽  
Raju Thomas ◽  
Ronald Davis ◽  
Douglas Slakey ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Helical Ct ◽  
Angio Ct

396: HSP27 Expression in Primary and Metastatic Renal Cell Carcinoma

2006 ◽  
Vol 175 (4S) ◽  
pp. 129-129
Author(s):  
Richard E. Zigeuner ◽  
Nikolaus Droschl ◽  
Volkmar Tauber ◽  
Peter Rehak ◽  
Cord Langner
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Hsp27 Expression
Sign in / Sign up

Export Citation Format

Share Document